טוען...
Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy
Sorafenib is used worldwide as a first-line standard systemic agent for advanced hepatocellular carcinoma (HCC) on the basis of the results of two large-scale Phase III trials. Conversely, hepatic arterial infusion chemotherapy (HAIC) is one of the most recommended treatments in Japan. Although ther...
שמור ב:
| הוצא לאור ב: | World J Hepatol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Baishideng Publishing Group Inc
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6177565/ https://ncbi.nlm.nih.gov/pubmed/30310535 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v10.i9.571 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|